These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 16327814

  • 1. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes.
    Hartwig UF, Nonn M, Khan S, Meyer RG, Huber C, Herr W.
    Bone Marrow Transplant; 2006 Feb; 37(3):297-305. PubMed ID: 16327814
    [Abstract] [Full Text] [Related]

  • 2. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
    Davies JK, Koh MB, Lowdell MW.
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
    [Abstract] [Full Text] [Related]

  • 3. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
    Hartwig UF, Nonn M, Khan S, Link I, Huber C, Herr W.
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):99-109. PubMed ID: 18158966
    [Abstract] [Full Text] [Related]

  • 4. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
    Nonn M, Herr W, Khan S, Todorova M, Link I, Thies J, Distler E, Kaltwasser M, Hoffmann J, Huber C, Hartwig UF.
    Transplantation; 2008 Nov 27; 86(10):1427-35. PubMed ID: 19034014
    [Abstract] [Full Text] [Related]

  • 5. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.
    Koh MB, Prentice HG, Lowdell MW.
    Bone Marrow Transplant; 1999 May 27; 23(10):1071-9. PubMed ID: 10373075
    [Abstract] [Full Text] [Related]

  • 6. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation.
    Meignin V, Peffault de Latour R, Zuber J, Régnault A, Mounier N, Lemaître F, Dastot H, Itzykson R, Devergie A, Cumano A, Gluckman E, Janin A, Bandeira A, Socié G.
    Exp Hematol; 2005 Aug 27; 33(8):894-900. PubMed ID: 16038781
    [Abstract] [Full Text] [Related]

  • 7. Comparative analysis of naïve and memory CD4+ and CD8+ T-cell subsets in bone marrow and G-CSF-mobilized peripheral blood stem cell allografts: impact of donor characteristics.
    Yakoub-Agha I, Saule P, Depil S, Grutzmacher C, Boulanger F, Magro L, Jouet JP, Dessaint JP, Labalette M.
    Exp Hematol; 2007 Jun 27; 35(6):861-71. PubMed ID: 17533040
    [Abstract] [Full Text] [Related]

  • 8. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.
    Michálek J, Collins RH, Vitetta ES.
    Neoplasma; 2003 Jun 27; 50(4):296-9. PubMed ID: 12937844
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.
    Zandvliet ML, van Liempt E, Jedema I, Kruithof S, Kester MG, Guchelaar HJ, Falkenburg JH, Meij P.
    J Immunother; 2011 Apr 27; 34(3):307-19. PubMed ID: 21389867
    [Abstract] [Full Text] [Related]

  • 10. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
    Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G.
    Haematologica; 2008 Feb 27; 93(2):248-56. PubMed ID: 18245650
    [Abstract] [Full Text] [Related]

  • 11. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.
    Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK.
    Blood; 2003 Sep 15; 102(6):2292-9. PubMed ID: 12763937
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease.
    Paz Morante M, Briones J, Canto E, Sabzevari H, Martino R, Sierra J, Rodriguez-Sanchez JL, Vidal S.
    Clin Exp Immunol; 2006 Jul 15; 145(1):36-43. PubMed ID: 16792671
    [Abstract] [Full Text] [Related]

  • 16. Differential effect of CD69 targeting on bystander and antigen-specific T cell proliferation.
    Alari-Pahissa E, Vega-Ramos J, Zhang JG, Castaño AR, Turley SJ, Villadangos JA, Lauzurica P.
    J Leukoc Biol; 2012 Jul 15; 92(1):145-58. PubMed ID: 22544938
    [Abstract] [Full Text] [Related]

  • 17. Ex vivo selection of recipient-type alloantigen-specific CD4(+)CD25(+) immunoregulatory T cells for the control of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
    Trenado A, Fisson S, Braunberger E, Klatzmann D, Salomon BL, Cohen JL.
    Transplantation; 2004 Jan 15; 77(1 Suppl):S32-4. PubMed ID: 14726768
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.